#United States #Boulder #Edgewise Therapeutics #EWTX #muscular dystrophies

Edgewise Therapeutics Grants Stock Options to New Employees

Edgewise Therapeutics, Inc. is making headlines with its latest announcement regarding inducement grants as part of its hiring strategy. Located in Boulder, Colorado, Edgewise is a prominent player in the biopharmaceutical sector, dedicated to developing innovative therapies for muscle diseases like muscular dystrophies and serious cardiac issues.

On April 30, 2026, the company declared that it had awarded inducement stock options to nine new non-executive employees. This action was in line with Edgewise’s 2024 Inducement Equity Incentive Plan, a strategy designed to attract and retain talented individuals in a competitive market. The total number of options granted amounted to 266,000 shares of the company’s common stock, giving these new hires a stake in Edgewise’s future growth.

Each employee received stock options priced at $30.96 per share, which was exactly the closing price of the shares on the grant date. Importantly, these options will vest over time, allowing 25% to become accessible on the one-year anniversary of each employee's start date. Subsequently, the remaining shares will vest at a rate of 1/48th monthly, contingent on continued employment with the company.

The decision to issue incentive stock options serves as a critical tool for Edgewise to attract skilled professionals in the biopharmaceutical landscape, as they are tailored to align employee performance with company goals and shareholder interests. These awards, categorized as inducements under Nasdaq Listing Rule 5635(c)(4), are vital for motivating new employees as they integrate into the company’s operations.

About Edgewise Therapeutics

Edgewise Therapeutics is at the forefront of developing therapeutics that specifically target muscle-related diseases, leveraging deep expertise in muscle physiology to advance its therapeutic pipeline. The biopharmaceutical company is devoted to delivering innovative treatments, including:

• - Sevasemten: A groundbreaking first-in-class oral fast skeletal myosin inhibitor that is currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies.
• - EDG-7500: A novel cardiac sarcomere modulator being evaluated for symptomatic hypertrophic cardiomyopathy in Phase 2 clinical trials.
• - EDG-15400: Another cardiac sarcomere modulator focused on heart failure treatment, which is presently in Phase 1 clinical development.

The dedicated team at Edgewise Therapeutics remains passionate about improving the quality of life for patients and families impacted by serious muscle diseases. The company invites interested individuals to learn more about its mission and innovations by visiting edgewisetx.com or following them on platforms like LinkedIn and X.

As Edgewise Therapeutics continues to expand its reach in the biopharmaceutical field, the recent inducement grants signal its commitment to building a talented workforce ready to push the boundaries of medical research and therapeutics. With the industry evolving rapidly, granting stock options is just one of the many ways companies like Edgewise are ensuring that they remain competitive in attracting top-tier talent, which ultimately benefits patients who depend on innovative treatments.

In conclusion, Edgewise Therapeutics has demonstrated its proactive approach to hiring by offering stock options as a crucial part of its recruitment strategy. This initiative is not only about expanding the team but also about fostering a workplace culture focused on collaboration and collective success in addressing the challenges of muscular diseases.